In this context, future studies employing genetic or pharmacological inhibition of TGF-β signaling in furin-overexpressing CRC models will be valuable to further delineate the pathway-specific contribution of TGF-β/ERK signaling to furin-driven tumor growth and chemoresistance. This evidence concerns the gene FURIN and neoplasm.